Yahoo Web Search

Sign In

  1. Also Try

Search results

  1. www.editasmedicine.comEditas Medicine

    Editas Medicine is a biotech company that uses CRISPR technology to develop genomic medicines for people with serious diseases. Learn about their pipeline, news, science, and culture.

    • Research and Pipeline

      Editas Medicine works with two distinct CRISPR nucleases:...

    • CRISPR Gene Editing

      Editas Medicine is a leading gene editing company dedicated...

    • For Patients

      The Editas Medicine Commitment. Engage regularly – seek out...

    • Who We Are

      Editas Medicine is a clinical stage genome editing company...

    • Join Our Team

      At Editas Medicine, we know that our greatest strength comes...

    • Investors

      Editas Medicine to Present Clinical Data from the RUBY and...

    • Newsroom

      EDITAS MEDICINE’S NEWSROOM Editas Medicine is a leading gene...

    • Get in Touch

      Get in Touch - Editas Medicine

  2. finance.yahoo.com › quote › EDITEditas Medicine, Inc. (EDIT) - Yahoo Finance

    Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing...

  3. Videos

    View all

  4. www.editasmedicine.com › aboutWho We Are | Editas Medicine

    Editas Medicine uses CRISPR technology to develop gene editing medicines for serious diseases, such as sickle cell disease and beta thalassemia. Learn about their mission, pipeline, leadership, and scientific founders.

  5. www.editasmedicine.com › gene-editing-pipelineResearch and Pipeline | Editas Medicine

    Editas Medicine is a biotechnology company that develops gene editing medicines for diseases with few or no treatments. It uses Cas9 and Cas12a nucleases to edit genes in vivo or ex vivo, and has clinical programs for sickle cell disease and beta thalassemia.

  6. en.wikipedia.org › wiki › Editas_MedicineEditas Medicine - Wikipedia

    Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. History

  7. ir.editasmedicine.comOverview | Editas Medicine

    May 10, 2024 · Editas Medicine is a biotechnology company developing gene editing therapies for rare diseases. See its stock price, upcoming events, and recent news on sickle cell disease and beta thalassemia trials.

  8. ir.editasmedicine.com › news-releases › news-release-detailsEditas Medicine Announces Positive Initial EDIT-301 Safety and...

    Jun 9, 2023 · CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced positive initial safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY trial and from the first transfusion-dependent beta thalassemia ...